Evolving Immunotherapy Combinations

At ASCO 2017, ZS’s Sharon Karlsberg and Dr. Suzanne Topalian, associate director of the Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, discuss evolving immunotherapy combinations.

At ASCO 2017, ZS’s Sharon Karlsberg and Dr. Suzanne Topalian, associate director of the Johns Hopkins Bloomberg-Kimmel Institute for Cancer ...

Beyond PD-L1: In Search of Better Biomarkers

ZS’s Sharon Karlsberg sat down with Dr. Suzanne Topalian, Associate Director of the Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, at ASCO 2017 to talk about where we are headed with immunotherapy in oncology.

ZS’s Sharon Karlsberg sat down with Dr. Suzanne Topalian, Associate Director of the Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, ...

Practical Issues When Treating With Immunotherapy

ZS’s Sharon Karlsberg sat down with Dr. Suzanne Topalian, associate director of the Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, at ASCO 2017 to talk about where we are headed with immunotherapy in oncology.

ZS’s Sharon Karlsberg sat down with Dr. Suzanne Topalian, associate director of the Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, ...

Real-World Evidence as a Mechanism for Patient-Centric Care

ZS’s Maria Whitman sat down with Dr. Yousuf Zafar, associate professor of medicine and public policy at Duke University, at ASCO 2017 to talk about the changing role of real-world evidence.

ZS’s Maria Whitman sat down with Dr. Yousuf Zafar, associate professor of medicine and public policy at Duke University, at ...

Real-World Evidence Compared to Randomized Clinical Trials

ZS’s Maria Whitman sat down with Dr. Yousuf Zafar, associate professor of medicine and public policy at Duke University, at ASCO 2017 to talk about the changing role of real-world evidence.

ZS’s Maria Whitman sat down with Dr. Yousuf Zafar, associate professor of medicine and public policy at Duke University, at ...

Real-World Evidence Today and Tomorrow: The Role of Key Stakeholders

ZS’s Maria Whitman sat down with Dr. Yousuf Zafar, associate professor of medicine and public policy at Duke University, at ASCO 2017 to talk about the changing role of real-world evidence.

ZS’s Maria Whitman sat down with Dr. Yousuf Zafar, associate professor of medicine and public policy at Duke University, at ...

Real-World Evidence: Can It Drive Differentiation and Demonstrate 'Value'?

ZS’s Maria Whitman sat down with Dr. Yousuf Zafar, associate professor of medicine and public policy at Duke University, at ASCO 2017 to discuss how real-world evidence can demonstrate value.

ZS’s Maria Whitman sat down with Dr. Yousuf Zafar, associate professor of medicine and public policy at Duke University, at ...

Barbara Burtness, MD, on chemotherapy and post-operative radiation in H&C cancers

Dr. Burtness, Disease Aligned Research Team Leader, Head and Neck Cancers Program Co-Director, Developmental Therapeutics Research Program, Yale Cancer Center, discusses how chemotherapy should be dosed when given with post-operative radiation in head and neck cancers

Dr. Burtness, Disease Aligned Research Team Leader, Head and Neck Cancers Program Co-Director, Developmental Therapeutics Research Program, Yale Cancer Center, ...

Aref Al-Kali, MD, regarding the Leukostat test in conjunction with midostaurin

Dr. Al-Kali, Acute Leukemia and Chronic Myeloid Disorders, Mayo Clinic, on whether physicians will adopt the Leukostat test, which was approved in conjunction with midostaurin

Dr. Al-Kali, Acute Leukemia and Chronic Myeloid Disorders, Mayo Clinic, on whether physicians will adopt the Leukostat test, which was ...

Mary Jo Fidler, MD, FASCO, offers opinion on integrating immunotherapies into treatment of SCLC

Dr. Fidler, Associate Professor, Medical Oncology, Rush University Medical Center, describes how immunotherapies should be integrated into the treatment of small cell lung cancer

Dr. Fidler, Associate Professor, Medical Oncology, Rush University Medical Center, describes how immunotherapies should be integrated into the treatment of ...